When Douglas Throckmorton, a long-time deputy director in the Center for Drug Evaluation and Research, retires in the coming months, the US Food and Drug Administration will lose a significant voice for the center’s drug shortage and controlled substance policy, as well as a prominent unifying force.
US FDA’s Drug Center Losing Shortages, Controlled Substance Leadership With Throckmorton Retirement
Throckmorton is known for enhancing the FDA’s drug shortage work by building bridges between the compliance and quality teams, as well as opioid oversight.
More from US FDA
• By
The April departures of Paul Kluetz and Marc Theoret follow resignations by other senior agency scientific staff and come on top of HHS’ plans to lay off 3,500 FDA employees.
• By
About 3,500 full-time FDA employees are expected to be laid off as part of a restructuring of the Health and Human Services Department and experts questioned whether the cuts could be implemented without harming FDA’s core mission.
• By
The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.